NEW YORK, NY / ACCESSWIRE / May 26, 2017 / BioCryst's shares skyrocketed on Thursday with trading volume significantly higher than usual after the company revealed positive results from a mid-stage close ranging study of its BCX7353 drug candidate. Shares of Aerie Pharmaceuticals also soared after positive results from its Mercury 2 trial were released. RDI Initiates Coverage on:

BioCryst Pharmaceuticals, Inc.https://ub.rdinvesting.com/news/?ticker=BCRX

Aerie Pharmaceuticals, Inc.https://ub.rdinvesting.com/news/?ticker=AERI

BioCryst Pharmaceuticals, Inc.'s shares closed up 31.19% on Thursday and was also one of the most actively traded stocks on the NASDAQ. Shares popped as much as 44% after the company's experimental hereditary angioedema (HAE) drug candidate, BCX7353, was revealed to show continued impressive results in a mid-stage dose ranging study based on a second interim analysis. BioCryst reported that the intent-to-treat population exhibited significant reductions in HAE attacks for both the 125 mg (p=0.004) and the 350 mg (p=0.014) doses, compared to placebo. The study had 44 patients who completed 28 days of treatment. Results had showed a 73% reduction in HAE attacks for the 125 mg dose, 37% reduction for the 250 mg dose and a 58% reduction for the 350 mg dose compared to placebo. No safety issues were related to the treatment according to the company. As BCX7353 is taken orally, it could offer a more convenient way to take an HAE medication.

Access RDI's BioCryst Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=BCRX

Aerie Pharmaceuticals, Inc. was one of the biggest gainers on the NASDAQ yesterday closing up 33.95% on tremendous volume. The clinical-stage biotech company had positive results in its Mercury 2 trial and investors were loving it. The Phase 3 study was designed to evaluate Aerie's Roclatan candidate, a potential treatment for glaucoma. Data from the study showed that Roclatan had achieved its primary endpoint by demonstrating statistical superiority over both Rhopressa (another drug of Aerie's with latanoprost, the current standard to treating glaucoma). The most exciting result was that Roclatan lowered intraocular eye pressure (IOP) by one to three mmHg more than either latanoprost or Rhopressa did on their own. The company also announced yesterday that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.

Access RDI's Aerie Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=AERI

Our Actionable Research on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDinvesting.com